Original Publication Date: 1 May, 2016
Publication / Source: Future Oncology
Authors: Yadhu Sharma, Altaf Ahmad, Samina Bashir, Asif Elahi & Farah Khan
The altered expression of SHP-1 (SH2 domain-containing protein tyrosine phosphatase) as a consequence of promoter hypermethylation or mutations has evidently been linked to cancer development. The notion of being a cancer drug target is conceivable as SHP-1 negatively regulates cell cycle and inflammatory pathways which are an inevitable part of oncogenic transformation.